←MEDPMedpace HoldingsOur view: UnattractiveFull analysisעברית
Updated 16 Nov 2026
The company · 1 · Who is this company?

Medpace runs drug trials for biotechs

Whole trials

designed and run for clients

Small biotechs

82% of 2025 revenue

Labs and imaging

in-house

Medpace designs studies, signs up hospitals, enrols patients, runs the tests and prepares the file for the regulator, mostly for small biotech companies.

The company · 2 · What exactly does it sell?

Service fees, plus costs passed through

What it earns
59.0%service fees for running trials
41.0%costs passed through at cost
About 29%each from obesity and cancer trials

The passed-through costs, like travel and hospital fees, earn Medpace nothing but swell its revenue.

The company · 3 · How does it make money?

Paid as each trial moves forward

$3.17Bof signed work not yet done
$873.4Mnew work signed last quarter
About 24%of signed work turned to sales a quarter

Medpace is paid as each trial progresses, so today's sales come from work signed earlier.

Is it a good business? · 4 · What gives it an edge?

For a small sponsor, delay costs most

About $800,000

lost sales per day of delay

11.5%

its 2025 service revenue growth

4.3%

IQVIA's trial business growth

Nothing locks a client in, though; the record has to be earned trial by trial.

Is it a good business? · 5 · What is the catch?

Larger rivals bid for the same work

IQVIAlarger, slower-growing
ICONrevenue grew 0.8% in 2025

Listed rivals: ICLR · IQV · FTRE · TMO

When a big drug maker buys a small biotech, its trials can move inside.

Is it a good business? · 6 · What does its record show?

Fast growth, fewer shares, more profit

Sales, $B
1.1
1.5
1.9
2.1
2.5
2.8
Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025last 12 mo
Sales$1.14B → $2.84Brevenue, 2021 to the past year
Profit17% → 21%operating profit per $1
Shares37.7M → 28.4Mshares, after buying them back

Overheads fell as a share of revenue, though passed-through costs blur the ratios.

Is it a good business? · 7 · How much room is there to grow?

The market it serves cannot be measured

About $145Ba year of trial spending
About 2,185mid- and late-stage trials started, 2025
About $1.5BMedpace's own service revenue

Nobody publishes how much small sponsors spend on outsourced trials.

Is it a good business? · 8 · Who is in charge?

The founder still runs it

1992August Troendle founded Medpace
19.6% → 19.1%his stake, cut by heavy sales this autumn

His autumn sales were not under a pre-set plan. About 2% of revenue comes from companies linked to him.

The story right now · 9 · Why does biotech funding matter?

Small biotechs spend what investors give them

0.88new work signed per $1 of sales in early 2026, as cancellations spiked
1.2 timesnew work signed against sales
About 29%of work in obesity trials

Small biotechs have no sales of their own; they fund trials with investors' money. When funding dries up or a drug fails, trials get cancelled.

The story right now · 10 · Why must growth slow?

Working faster through orders cannot last

  1. Signed work piles up$3.17B.
  2. Worked off faster24% a quarter, not 18%.
  3. Sales jumpAhead of orders.
  4. Pace returns to normalGrowth slows.

Unless new orders climb faster than sales, revenue must slow to the pace orders allow.

The story right now · 11 · What changed lately?

New work signed outran sales

$873.4Mnew work signed in the quarter
+8.5%revenue, to $716.0M
$3.17Bsigned work, up 5.6%

Solid quarter

Cancellations ran at the high end of normal, blamed on failed drugs rather than funding; most analysts now rate the shares a hold.

The story right now · 12 · What is everyone arguing about?

Scare over, or arithmetic ahead?

Many investors think

A fine business at a full price, scare over

We think

Revenue ran ahead of orders, so growth must slow

Against us: record orders and eight quarters beating forecasts.

The price and our view · 13 · What is a share worth?

The price leaves little room if orders stall

$408what we think a share is worth
$408our value
Attractive
below $327
Neutral
Unattractive
above $490
$252gloomy: growth halves, less kept per $1
$408our estimate: experts' path, then slowing
$506sunny: growth beats the forecast by a quarter

Value per share in three futures. None is a prediction of the share price.

We estimate what a share is worth from the cash the business should earn over many years. Our rule: buy only when the price is at least a fifth below our estimate, as a cushion for being wrong.

The price and our view · 14 · How could we be wrong?

Orders can vanish fast

Orders can vanishBiggest

Cancellations spike.

Obesity trials winding downShowing now

The growth engine fades.

Biotechs need moneyWatch

Funding drives orders.

Obesity share of ordersUnknown

Not disclosed.

A few clients matter more than before, and the founder decides.

The price and our view · 15 · How will we know?

February tests orders and 2027

New work stays above 1.2 times salesGood sign
Cancellations fall backGood sign
Biotech funding dries upBad sign
FEB 20278

Fourth-quarter 2026 results, 8 February. Companies report every three months; each report is a test of the story.

Our view also changes on price alone: if the shares fall to within a fifth of our estimate, we move to Neutral.

The price and our view · 16 · So, what do we think?

A share-taking trial runner, priced for steady orders

$408our value
Attractive
below $327
Neutral
Unattractive
above $490

UnattractiveHigh conviction

Medpace runs complete drug trials for small biotechs, winning work from bigger rivals while buying back shares. But orders can vanish fast, obesity trials are winding down and revenue has outgrown orders.

↑ ↓ to move · C for contents